Seeking Alpha

More on Zalicus (ZLCS +6.25%) Q2: company has again extended its partnership with Novartis...

More on Zalicus (ZLCS +6.25%) Q2: company has again extended its partnership with Novartis (NVS), "validating the value" of Zalicus' cHTS technology for developing cancer treatments. Zalicus is also on track to start Phase 2a trials of Z160, a drug for neuropathic pain, and to report results of a Phase IIb trial for Synavive, which is used for rheumatoid arthritis. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)